New hope for hard-to-treat lung cancer: drug duo targets HER2
NCT ID NCT07264816
First seen Jan 08, 2026 · Last updated Jun 16, 2026 · Updated 26 times
Summary
This study tests a combination of two drugs, BL-M07D1 and pembrolizumab, in people with advanced HER2-positive non-small cell lung cancer that cannot be removed by surgery. The goal is to see if the treatment shrinks tumors and controls the disease. About 80 adults aged 18 to 75 will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, China
Contact
Conditions
Explore the condition pages connected to this study.